Home -> Law Blog Directory -> Local Law Blogs Blogs -> Southwest Virginia Law Blog
(866) 635-2689 for Personal Injury or (866) 635-9402 for Criminal Defense
Find a Local Lawyer
Divorce (866) 635-6190
Personal Injury (866) 635-2689
Criminal Defense (866) 635-9402
Local Law Blogs
: Southwest Virginia Law BlogToday's administrative law case
By Steven R. Minor
One of the cases is about whether there is an implied cause of action to enforce a statute against a state agency that has refused to make a final decision, claiming lack of sufficient information from the aggrieved party.
I observe this statute in the Administrative Process Act:
§ 2.2-4029. Court judgments. Unless an error of law as defined in 2.2-4027 appears, the court shall dismiss the review action or affirm the agency regulation or decision. Otherwise, it may compel agency action unlawfully and arbitrarily withheld or unreasonably delayed except that the court shall not itself undertake to supply agency action committed by the basic law to the agency. Where a regulation or case decision is found by the court not to be in accordance with law under 2.2-4027, the court shall suspend or set it aside and remand the matter to the agency for further proceedings, if any, as the court may permit or direct in accordance with law.
The same language appears in the federal act, 5 U.S. Code §?706(1).
I don't know whether this language affects the issues in the case on appeal, but I know that the one time I brought such a claim under federal law, the agency mooted the case by making a prompt decision.
Full post as published by Southwest Virginia Law Blog on April 15, 2020 (boomark / email).
Gleevec
Possible Case of Kidney Damage Reported
Hampton Inn
Third Case of Legionnaires' Disease Linked to McHenry Hampton Inn Hot Tub
18-Wheeler Accident Case Settled for $600,000
18-Wheeler Accident Case Settled for $600,000
Jury Awards $29M in Elder Abuse Case
Jury Awards $29M in Elder Abuse Case
Female Sales Reps Win Gender Case Against Novartis
Female Sales Reps Win Gender Case Against Novartis









